ISOLATION OF RARE CELLS USING BIORECEPTOR FERROFLUIDS

Information

  • Research Project
  • 3508816
  • ApplicationId
    3508816
  • Core Project Number
    R44HL046073
  • Full Project Number
    5R44HL046073-03
  • Serial Number
    46073
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/15/1991 - 33 years ago
  • Project End Date
    8/31/1994 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1993 - 31 years ago
  • Budget End Date
    8/31/1994 - 30 years ago
  • Fiscal Year
    1993
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/20/1993 - 31 years ago
Organizations

ISOLATION OF RARE CELLS USING BIORECEPTOR FERROFLUIDS

This phase II proposal embodies an ambitious and challenging plan for the development of revolutionary and highly selective and efficient cell separation systems. Targeted separation systems will offer desirable and needed improvements and open new opportunities in diagnostics and medical applications, such as fetal cell analysis from maternal blood, and early cancer detection. The specific objectives of this work are to develop the ferrofluids or magnetic capture particles, to have optimal properties for cell selection, colloidal stability, and magnetic susceptibility, while having all other properties which are compatible with the intended system. In addition, the magnetic separation devices will be designed and optimized for flow, collection efficiency and efficient recovery and concentration of cells. Thirdly, an objective of this plan is to develop the schemes and procedures to isolate and concentrate cells, specifically the rare cells which are of vital interest to the medical community and in which few technologies have traversed. Based upon our extensive experience in and knowledge of ferrofluids and separation technology as well as the specific pioneering work as detailed in our Phase I report, we propose a highly sophisticated technology to the medical community with potential low cost, which can offer many needed advantages. In addition, our system has great potential in opening new doors in medicine, as separation and selection technology has wide application.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    IMMUNICON CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    HUNTINGDON VALLEY
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    19006
  • Organization District
    UNITED STATES